Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Renal Cell CancerKidney Cancer
Interventions
DRUG

Sunitinib Malate

50 mg by mouth daily for 4 weeks, then 2 weeks off.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER